6:27 PM
 | 
Jan 29, 2013
 |  BC Extra  |  Company News

Actavis, Amgen disclose compounds in biosimilars deal

Actavis Inc. (NYSE:ACT) and Amgen Inc. (NASDAQ:AMGN) disclosed on Friday the four cancer drugs for which they are developing biosimilars under a 2011 deal. The drugs include Herceptin trastuzumab, Avastin...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >